



Available online at
ScienceDirect
www.sciencedirect.com

Elsevier Masson France
EM|consulte
www.em-consulte.com/en



SCIENTIFIC EDITORIAL

Editorial

Éditorial



Ariel Cohen*, Yves Cottin, Yves Juilliere, on behalf of the Editorial Committee

Service de cardiologie, hôpital Saint-Antoine, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France

Received 20 August 2018; accepted 20 August 2018
Available online 14 January 2019

The past 10 years have been tremendously exciting, since the launch in 2008 of Archives of Cardiovascular Diseases, the official journal of the French Society of Cardiology.

The journal has matured over this period, and many important scientific breakthroughs and advances have been reported. In addition to the printed journal, articles are available to the global scientific community through Elsevier's e-platform, Science Direct.

The quality of the journal continues to improve, reflecting the ever-increasing quality of the submitted manuscripts, the outstanding contributions of the reviewers and the editorial board, and the substantial efforts and support provided by Clarisse Barillé (editorial secretary), Sophie Rushton-Smith (technical editor), and Emanuele Di Angelantonio (statistical consultant). Consequently, the journal's impact factor has again risen, to 2.37 in 2017.

The task, however, is broad, and the editorial board and Elsevier continue to examine ways to further improve the quality of our journal. One evolution is the introduction of a "graphical abstract", starting in 2019, which provides readers with an immediate and visual summary of the key aspects of a paper. The first graphical abstracts will be published in review articles and will then be extended to original articles.

The second focus concerns translational cardiology, with recent attempts to stimulate the interface between basic research and its clinical consequences. This objective should be facilitated by involvement of the "Young Cardiologists in Training College".

* Corresponding author.

E-mail address: ariel.cohen@sat.aphp.fr (A. Cohen).

The thematic issues of the journal were inaugurated this year, and their success is undeniable. The latest supplement, on cardiovascular imaging of heart disease entitled "Cardiac Imaging in Cath Lab", is a success in terms of the content of the editorial, the original articles and the reviews, as well as the overall quality of iconography and diversity of topics covered. Philippe Acar is to be congratulated for being the instigator and coordinator of these thematic issues dedicated to paediatric cardiology.

One of the goals of the journal is to encourage the involvement of clinicians and researchers from the global cardiology community, with more contributions and submissions from Europe, the United States, Africa, Asia and elsewhere. Our journal must – through publication of the best scientific research and opinion – be recognized as one of the leading journals in cardiovascular science, alongside other journals that have been established for a longer period.

Our task is significant, and our objectives even more ambitious. The editorial board of the journal is tasked with promoting contributions and recent advances across the diversity of cardiovascular science. The contributions of the French cardiology community to innovations and therapeutic progress are undeniable. Our journal now aims to be the bearer and the vector of the dynamism of all cardiology actors worldwide.

We – the editorial board – remain attentive and available to you – our readers and contributors – in our joint effort to further enhance the dissemination and global impact of our journal, Archives of Cardiovascular Diseases.

Disclosure of interest

Ariel Cohen: Research Grant; Modest; RESICARD. Consultant/Advisory Board; Modest; Amgen, Astra-Zeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Novartis.

Yves Juillière: Participation on boards for the following companies: Abbott Vascular, Bayer, Boston Scientific, St. Jude Medical and Novartis. Participation in sponsored investigational trials and/or meetings as speaker or chairperson for the companies Abbott Vascular, Amgen, Bayer, Bristol-Myers Squibb, Boston Scientific, GSK, The Medicines Company, MSD/Schering-Plough, Novartis, Roche Diagnostics, Sanofi-Aventis, Servier and St. Jude Medical.

Yves Cottin: Participation on boards for the following companies: Bayer, Boehringer, Servier, Pfizer-BMS, Sanofi-Aventis, and Novartis. Participation in sponsored investigational trials and/or meetings as speaker or chairperson for the companies Amgen, Bayer, Bristol-Myers Squibb, MSD/Schering-Plough, Novartis, Sanofi-Aventis, Servier, Novonordis and Lilly.